Table 3.
PSA outcomes and %ARNL in AR-V7+ patients and AR-V7- patients with or without ARv567es expression
| Group 1 | Group 2 | Group 3 | ||
|
AR-V7-/
and ARv567es- n = 5 |
AR-V7-/ ARv567es+n = 13 |
All AR-V7+n = 36 |
Total n = 54 |
|
| PSA50 at C5D1, n (%) | 4 (80.0%) | 7 (53.9) | 13 (36.1) | 24 (44.4) |
| p-value vs Group 1 | 0.31 | 0.26 | ||
| p-value vs Group 2 | 0.06 | |||
| Trend Group 1 > Group 2 > Group 3 | 0.1748 | |||
| PSA50 at any time, n (%) | 5 (100.0) | 9 (69.2) | 21 (58.3) | 35 (64.8) |
| p-value vs Group 1 | 0.16 | 0.49 | ||
| p-value vs Group 2 | 0.07 | |||
| Trend Group 1 > Group 2 > Group 3 | 0.33 | |||
| GROUP 1 | GROUP 2 | GROUP 3 | ||
|
AR-V7-/
and ARv567es- n = 3 |
AR-V7-/ ARv567es+n = 5 |
All AR-V7+ n = 16 |
Total n = 24 |
|
| C1D1 %ARNL, mean (SD) | 56.9 (19.2) | 67.6 (11.6) | 62.5 (14.3) | 62.9 (14.1) |
| C1D8 %ARNL, mean (SD) | 44.1 (4.8) | 41.0 (14.1) | 62.2 (15.2) | 55.5 (16.8) |
| C1D8 – C1D1 %ARNL, mean (SD) | −12.9 (15.4) | −26.7 (25.4) | −0.4 (13.2) | −7.4 (19.1) |
| p-value vs Group 1 | 0.52 | 0.08 | ||
| p-value vs Group 2 | 0.52 | |||
| Trend Group 1 > Group 2 > Group 3 | 0.08 | |||
AR, androgen receptor; ARNL, androgen receptor nuclear localization; C1D1, Cycle 1 Day 1; C1D8, Cycle 1 Day 8; C5D1, Cycle 5 Day 1; PSA50, 50% reduction from baseline in prostate-specific antigen; SD, standard deviation.